Transaction · 0001302443-26-000018

Winningham Rick E

Winningham Rick E, CEO, reported a transaction classified as return at Theravance Biopharma, Inc. involving 515000.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DCEO
TBPHTheravance Biopharma, Inc.
Trade date
Sep 23, 2026
Filing date
Sep 25, 2026
View on SEC Insider profile
Estimated value—Shares × reported price
Shares traded515kPrice unknown
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

TBPH price since this filing

Daily closing prices, with the filing date and available return windows
TBPH · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.1%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
return
Code D
Identifier
0001302443-26-000018
Share Option (Right to Buy)
Transaction date
Sep 23, 2026
Filed Sep 25, 2026, 12:27 AM · 2d delay
Shares
515,000 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
Filing-only score

-14 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF EXECUTIVE OFFICER

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub…

  2. F2

    At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time w…

  3. F3

    As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time…

  4. F4

    At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled…

Original filing · 0001302443-26-000018
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TBPH